Elvina Almuradova· @Dr_ElvinaA · X·· 22 hours agoScore45
Body
Selective CDK4 inhibition in endocrine-resistant #BreastCancer: phase 2 results for atirmociclib + fulvestrant, an Oral Abstract Session at #ESMO26 @OncoAlert @Larvol
161 views · 6 likes · 5 reposts · 0 replies
Conference abstracts
1842Omatched by Proffered paper 2: Breast cancer, early and advanced stage
Efficacy and safety of atirmociclib (ATI) + fulvestrant (FUL) in patients (pts) with HR+/HER2– advanced/metastatic breast cancer (mBC) who progressed on prior CDK4/6 inhibitor (CDK4/6i) in a randomized phase 2 study (FOURLIGHT-1)
https://esmocongress.esmo.orgSource: Elvina Almuradova · x.com